No Data
No Data
Matinas BioPharma To Carry Out 1-for-50 Reverse Stock Split On September 3rd, 2024
NYSE American New 52-Week Highs And Lows
Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript Summary
Earnings Call: Matinas BioPharma Outlines Progress on MAT2203 and LNC Platform
Matinas BioPharma Releases Updated Corporate Presentation
No Data
No Data